

Supporting European academy and industry for the fast progress of translational medicine

Facilities, resources and services to support cutting edge research



EATRIS countries

Bulgaria, Czech Republic,
Finland, France, Italy, Latvia,
Luxembourg, Netherlands,
Norway, Portugal, Slovenia,
Spain, Sweden



110
**Research
Institutes**



5 Scientific Platforms

ATMPs, Biomarker,
Imaging & Tracing, Small
Molecules, Vaccines



Legal status

Non-profit, ERIC
legal status

Examples of key actions



EATRIS supporting the European Health Data Space



Developing tools to ensure the highest quality and reproducibility of data generated during the research and innovation value chain



Accelerating capacities of the use of health data for the clinical decision-making processes



Cooperating with other health data-related initiatives to improve the efficiency of the value chain in the health care domain

EATRIS Health-data Actions and Activities



EOSC-life

Together with other Ris
reuse of health data



EATRIS-Plus

Certificate of Quality
for omic-data in
diagnostic processes



MULTIOMIC data integration

For Metabolic
disorders (within
EATRIS-Plus)



EU-PEARL

building master
protocols for efficient
generation of data from
platform clinical trials



HEALTHY- CLOUD

Working with ECRIN
and BBMRI for the
establishment of the
pan-European Health
data portal

EATRIS Scientific support



- **Finding partners for COVID19 Research**
Requests: 40 institutions within the COVID19 Resources and Activities Database
- **EATRIS COVID-19 Research Forum** An interactive platform for EATRIS COVID-19 researchers to interact, find collaborators, exchange protocols, samples, ideas...)
- **EATRIS Task force** to evaluate proposal ideas

The European Research Infrastructure for Translational Medicine (EATRIS)

EATRIS Members - SARS-CoV-2 Activities and Services

Version 1.3 - April 9, 2020


More information: www.eatris.eu/insights/eatris-covid-19

To access these resources, please contact Chris Tieken, EATRIS Business Development Manager: christieken@eatris.eu



	Institution	Country	SARS-CoV-2 Activities and Services
1	University Medical Centre Utrecht	NL	<ul style="list-style-type: none">- Sampling of COVID-19 suspected patients in the emergency response unit and in the ICU (medium/high).- Plasma and cell isolation and Olink technology for ongoing mechanisms determination.- Service provider for the Olink technology and capacity to run assays for external groups.- Luminex assay for ~150 markers available for quantification.- ARCADIA and UDAIR available to process blood/plasma/serum, urine and liquor (CSF).
2	Istituto Nazionale Tumori- IRCCS G. Pascale	IT	<ul style="list-style-type: none">- Coordination of a Phase 2 clinical trial with Tocilizumab (monoclonal anti-IL-6) for COVID-19 infected patients. (academic nationwide study approved by the Italian Drug Regulatory Agency with 300 patients in addition to an observational study on open label participants).- High trough put screening technology and FDA-approved drugs library to be screened in cellular based system to identify molecules that can interfere with virus infection ; or that can reduce cytokines production.- Multiplexing technology to measure up to 48 cytokines/chemokines on the same sample either patient's plasma (to evaluate cytokines storm induced by the virus and the effect of drugs that counteract it), or cell supernatants.- NMR-based measurement of oxidative stress and metabolism in multiplexing in patient's plasma to eventually evaluate early deterioration and drop in oxygen saturation.
3	Biomedical Primate Research Centre	NL	<ul style="list-style-type: none">- Macaque model for SARS-CoV-2 in development.- Ongoing vaccine study from a third party to study vaccine safety and efficacy in a rhesus macaque model.- COVID-19 Macaque models (Cyno and Rhesus) for vaccine and drug studies with license in place.- COVID-19 Marmoset models available (license under approval).A221Retrieving data. Wait a few seconds and try to cut or copy again.- Capacity to analyse viral load (PCR, culture), immunological and clinical parameters (including CT scans) in addition to providing pathology reports (gross pathology and histopathology).- Lung lesions can be followed real-time using in house (pet)-CT in addition to telemetry (home cage activity and body temperature) and virological and immunological assays.

EATRIS COVID-19 Resources and Activities Database available online e.g Challenge models e.g hamster, NHPs, access to SARS-COV-2 Virus, Patient samples....



COVID-19 Partnering Requests



Project Type	Project Description	Account Name	Account Type	Country	Status
Research service	BSL-3 Facilities for SARS-COV-2 Virus Candidate Testing	Latvian Biomedical Research and Study Center	Research Institute	Latvia	Matching
Consortium building	Erasmus Plus Call- Coronavirus Digital Education	University of Foggia	University	Italy	4 Institutions Matched
Research service	Rapid COVID-19 Test Validation	Perron institute	Research Institute	Australia	1 Institution Matched
Research service	Covid-19 Samples	Max Planck Institute of Experimental Medicine	Research Institute	Germany	1 Institution Matched
Consortium building	Infrared heating systems to reduce COVID-19 infections	University of Istanbul	Research Institute	Turkey	Ongoing
Research service	Manufacturing for Large scale production of viral proteins	BioMaric	Pharmaceutical company	Belgium	1 Institution Matched
Research service	COVID-19 Subject Trial	LIITA CARE	SME/Biotech	Denmark	1 Institution Matched
Expert advice	BSL3 Laboratory Certification	Latvian Biomedical Research and Study Centre	Research Institute	Latvia	Completed
Research service	Availability of SARS-COV-2 Virus	Materia Medica	SME/Biotech	Russia	3 Institutions Matched
Research service	Petrovax_SAR-COV-2 Animal Models	Petrovax	Pharmaceutical company	Russia	3 Institutions Matched
Consortium building	Exogenous Therapeutics_Lung Models	Exogenous Therapeutics	SME/Biotech	Portugal	3 Institutions Matched
Expert advice	SARS-COV-2 Virus Production	Vall d'Hebron Research Institute (VHIR)	EATRIS institution	Spain	Completed
Consortium building	EUREKANETWORK_COVID-19	Kuste Biopharma	SME/Biotech	France	1 institution Matched
Consortium building	Animal Models for Antiviral studies for SARS-COV-2 Vaccine candidate	Hercules Pharmaceutical	SME/Biotech	Netherlands	1 institution Matched
Consortium building	TRANSVAC-Immunogenecity Studies	Vall d'Hebron Research Institute (VHIR)	EATRIS institution	Spain	Ongoing
Consortium building	TRANSVAC- NHPs	University of Santiago de Compostela (USC)	University	Spain	Received Funding
Consortium building	TRANSVAC- Animal Models/Regulaory Support for funded EC Project	Københavns Universitet	University	Denmark	Received Funding
Consortium building	COVID-19 Lung Cells and Models	University of Helsinki	EATRIS institution	Finland	3 Institutions Matched
Consortium building	COVID-19 Cell Based Antiviral Assays	University of Zagreb	University	Croatia	3 Institutions Matched

**19 Projects matched through the COVID-19 Response Group
at various stages of development**

Joining forces with BBMRI-ERIC and ECRIN



- **Fast response service to COVID-19 now available!**
 - ✓ List of complementary services/resources identified by each RI
 - ✓ One single contact point
 - ✓ Response within 72 hours
- **Joint statement: 5 recommendations to accelerate COVID-19 Research**
- **Scientific publication: Biomarker Research and Development for COVID-19: European medical research infrastructures call for global coordination (*accepted, Clinical Infectious Diseases*)**

Biomarker Research and Development for Coronavirus Disease 2019 (COVID-19): European Medical Research Infrastructures Call for Global Coordination

Emanuela Oldoni,¹ Alain van Gool,² Laura García Bermejo,³ Andreas Scherer,⁴ Michaela Th. Mayrhofer,⁵ Francesco Florindi,⁵ Jacques Demotes,⁶ Christine Kubiak,⁶ Anne-Charlotte Fauvel,¹ Florence Bietrix,¹ Anton Ussi,¹ and Antonio L. Andreu¹

¹European Infrastructure for Translational Medicine (EATRIS), Amsterdam, The Netherlands, ²Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands, ³Department of Pathology, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain, ⁴Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland, ⁵Biobanking and BioMolecular Resources Research Infrastructure-European Research Infrastructure Consortium (BBMRI-ERIC), Graz, Austria, and ⁶European Clinical Research Infrastructures Network (ECRIN), Paris, France

Scientific Publication: October 2020